Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Calogero Lauricella
Observed names:
C Lauricella,
C. Lauricella
Institution:
Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda
Observed institutions:
Janssen (Belgium),
Johns Hopkins University,
University of Milan,
Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico,
Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda,
IFOM,
Sigma Tau (Italy),
Candiolo Cancer Institute,
University of Turin
show all 9
ORCID:
0000-0003-4815-3359
Observed ORCID:
0000-0003-4815-3359
OpenAlex ID:
A5091227333
Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies
2014
·
Chetan Bettegowda
, Mark Sausen
, et al.
·
Science Translational Medicine
·
5,516
Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients
2015
·
Giulia Siravegna
, Benedetta Mussolin
, et al.
·
Nature Medicine
·
1,152
Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial
2016
·
Andrea Sartore-Bianchi
, Livio Trusolino
, et al.
·
The Lancet Oncology
·
1,113
PDF
Amplification of the MET Receptor Drives Resistance to Anti-EGFR Therapies in Colorectal Cancer
2013
·
Alberto Bardelli
, Simona Corso
, et al.
·
Cancer Discovery
·
715
Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial
2013
·
Marina Chiara Garassino
, Olga Martelli
, et al.
·
The Lancet Oncology
·
495
Assessment of a HER2 scoring system for colorectal cancer: results from a validation study
2015
·
Emanuele Valtorta
, Cosimo Martino
, et al.
·
Modern Pathology
·
336
PDF
Blockade of EGFR and MEK Intercepts Heterogeneous Mechanisms of Acquired Resistance to Anti-EGFR Therapies in Colorectal Cancer
2014
·
Sandra Misale
, Sabrina Arena
, et al.
·
Science Translational Medicine
·
278
PDF
Erratum: Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients
2015
·
Giulia Siravegna
, Benedetta Mussolin
, et al.
·
Nature Medicine
·
262
PDF
Mutations of KRAS and BRAF in Primary and Matched Metastatic Sites of Colorectal Cancer
2008
·
Salvatore Artale
, Andrea Sartore-Bianchi
, et al.
·
Journal of Clinical Oncology
·
252
PDF
KRAS gene amplification in colorectal cancer and impact on response to EGFR‐targeted therapy
2013
·
Emanuele Valtorta
, Sandra Misale
, et al.
·
International Journal of Cancer
·
191
PDF
BRAF codons 594 and 596 mutations identify a new molecular subtype of metastatic colorectal cancer at favorable prognosis
2015
·
C. Cremolini
, M. Di Bartolomeo
, et al.
·
Annals of Oncology
·
173
PDF
KRAS mutations affect prognosis of non-small-cell lung cancer patients treated with first-line platinum containing chemotherapy
2015
·
Mirko Marabese
, Monica Ganzinelli
, et al.
·
Oncotarget
·
100
PDF
Novel CAD-ALK gene rearrangement is drugable by entrectinib in colorectal cancer
2015
·
Alessio Amatu
, Alessio Somaschini
, et al.
·
British Journal of Cancer
·
88
PDF
TAILOR: Phase III trial comparing erlotinib with docetaxel in the second-line treatment of NSCLC patients with wild-type (wt) EGFR.
2012
·
Marina Chiara Garassino
, Olga Martelli
, et al.
·
Journal of Clinical Oncology
·
54
Value of KRAS as prognostic or predictive marker in NSCLC: results from the TAILOR trial
2015
·
E. Rulli
, M. Marabese
, et al.
·
Annals of Oncology
·
47
RAS as a positive predictive biomarker: focus on lung and colorectal cancer patients
2021
·
Umberto Malapelle
, Francesco Passiglia
, et al.
·
European Journal of Cancer
·
44
Multi-Center Evaluation of the Fully Automated PCR-Based Idylla™ KRAS Mutation Assay for Rapid KRAS Mutation Status Determination on Formalin-Fixed Paraffin-Embedded Tissue of Human Colorectal Cancer
2016
·
Jérôme Solassol
, Julie Vendrell
, et al.
·
PLoS ONE
·
39
PDF
TAILOR: A phase III trial comparing erlotinib with docetaxel as the second-line treatment of NSCLC patients with wild-type (wt) EGFR.
2012
·
Marina Chiara Garassino
, Olga Martelli
, et al.
·
Journal of Clinical Oncology
·
34
Selinexor versus doxorubicin in dedifferentiated liposarcoma PDXs: evidence of greater activity and apoptotic response dependent on p53 nuclear accumulation and survivin down‐regulation
2021
·
Valentina Zuco
, Sandro Pasquali
, et al.
·
Journal of Experimental & Clinical Cancer Research
·
31
PDF
Liquid Biopsy for Small Cell Lung Cancer either De Novo or Transformed: Systematic Review of Different Applications and Meta-Analysis
2021
·
Elio Gregory Pizzutilo
, Martino Pedrani
, et al.
·
Cancers
·
29
PDF
Activity of osimeRTInib in non-small-cell lung Cancer with UNcommon epidermal growth factor receptor mutations: retrospective Observational multicenter study (ARTICUNO)
2024
·
E.G. Pizzutilo
, A.G. Agostara
, et al.
·
ESMO Open
·
23
PDF
Assessment of droplet digital polymerase chain reaction for measuring BCR‐ABL1 in chronic myeloid leukaemia in an international interlaboratory study
2021
·
Stuart Scott
, Ashley Cartwright
, et al.
·
British Journal of Haematology
·
18
PDF
TRKA expression and NTRK1 gene copy number across solid tumours
2018
·
Gianluca Mauri
, Emanuele Valtorta
, et al.
·
Journal of Clinical Pathology
·
17
Pooled Analysis of Clinical Outcome of Patients with Chemorefractory Metastatic Colorectal Cancer Treated within Phase I/II Clinical Studies Based on Individual Biomarkers of Susceptibility: A Single-Institution Experience
2017
·
Andrea Sartore-Bianchi
, Alessio Amatu
, et al.
·
Targeted Oncology
·
17
PDF
Rapid Detection and Quantification of Mycobacterium tuberculosis DNA in Paraffinized Samples by Droplet Digital PCR: A Preliminary Study
2021
·
Maria Antonello
, Rossana Scutari
, et al.
·
Frontiers in Microbiology
·
16
Show more works
View as search
Works count:
68
Citation count:
11,120
H-index:
21
I10-index:
25
Year
Topic
Type